SMT201800473T1 - Nuovi derivati di benzimidazolo come inibitori di chinasi - Google Patents

Nuovi derivati di benzimidazolo come inibitori di chinasi

Info

Publication number
SMT201800473T1
SMT201800473T1 SM20180473T SMT201800473T SMT201800473T1 SM T201800473 T1 SMT201800473 T1 SM T201800473T1 SM 20180473 T SM20180473 T SM 20180473T SM T201800473 T SMT201800473 T SM T201800473T SM T201800473 T1 SMT201800473 T1 SM T201800473T1
Authority
SM
San Marino
Prior art keywords
kinase inhibitors
benzimidazole derivatives
novel benzimidazole
novel
derivatives
Prior art date
Application number
SM20180473T
Other languages
English (en)
Italian (it)
Inventor
Tomasz Rzymski
Michal Galezowski
Wojciech Czardybon
Raymond Horvath
Katarzyna Wiklik
Mariusz Milik
Krzysztof Brzózka
Renata Windak
Magdalena Zawadzka
Pawel Guzik
Ewelina Wincza
Marta Prokop
Aleksandra Sabiniarz
Wieslaw Marek Cholody
Original Assignee
Selvita S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita S A filed Critical Selvita S A
Publication of SMT201800473T1 publication Critical patent/SMT201800473T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM20180473T 2012-12-21 2013-12-20 Nuovi derivati di benzimidazolo come inibitori di chinasi SMT201800473T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223265.8A GB201223265D0 (en) 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors
PCT/EP2013/077754 WO2014096388A2 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors
EP13811246.1A EP2935244B1 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
SMT201800473T1 true SMT201800473T1 (it) 2018-11-09

Family

ID=47682482

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180473T SMT201800473T1 (it) 2012-12-21 2013-12-20 Nuovi derivati di benzimidazolo come inibitori di chinasi

Country Status (23)

Country Link
US (2) US9388192B2 (OSRAM)
EP (1) EP2935244B1 (OSRAM)
JP (1) JP6169185B2 (OSRAM)
KR (1) KR101779272B1 (OSRAM)
CN (1) CN104936951B (OSRAM)
AU (1) AU2013366513B2 (OSRAM)
BR (1) BR112015014701B8 (OSRAM)
CA (1) CA2896156C (OSRAM)
CY (1) CY1120692T1 (OSRAM)
DK (1) DK2935244T3 (OSRAM)
ES (1) ES2688395T3 (OSRAM)
GB (1) GB201223265D0 (OSRAM)
HR (1) HRP20181429T8 (OSRAM)
HU (1) HUE039376T2 (OSRAM)
IL (1) IL239193A0 (OSRAM)
LT (1) LT2935244T (OSRAM)
MX (1) MX369589B (OSRAM)
PL (1) PL2935244T3 (OSRAM)
PT (1) PT2935244T (OSRAM)
RS (1) RS57658B1 (OSRAM)
SI (1) SI2935244T1 (OSRAM)
SM (1) SMT201800473T1 (OSRAM)
WO (1) WO2014096388A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
CN105916503B (zh) 2014-01-14 2020-04-14 米伦纽姆医药公司 杂芳基化合物和其用途
JP2017502092A (ja) 2014-01-14 2017-01-19 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ヘテロアリール及びその使用
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
CA2997556C (en) 2015-09-03 2020-12-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1a and uses thereof
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
EP3812379A1 (en) 2016-12-09 2021-04-28 Vertex Pharmaceuticals Incorporated Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
US9855255B1 (en) 2017-05-26 2018-01-02 King Saud University Substituted naphthyridinyl hydrazines as anti-liver cancer agents
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
AU2018351059B2 (en) 2017-10-19 2022-05-12 Teijin Pharma Limited Benzimidazole derivatives and their uses
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
KR20210059663A (ko) * 2019-11-15 2021-05-25 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
CN113491691B (zh) * 2020-04-02 2023-04-14 深圳贝瑞生物医药科技有限公司 一种用于制备抗肿瘤药物或14-3-3η蛋白抑制剂的化合物
KR102854745B1 (ko) * 2020-04-23 2025-09-04 진크래프트 주식회사 R-point 조절 단백질 복합체를 유효성분으로 포함하는 폐암 치료용 약학적 조성물, 상기 복합체의 형성 여부를 이용한 폐암 치료제 스크리닝 방법 및 폐암 진단 방법
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
JP2025525510A (ja) 2022-07-29 2025-08-05 アールワイヴィーユー セラピューティクス エス.エー. Bcl-2阻害剤を含む癌併用療法
CA3259252A1 (en) 2022-07-29 2024-02-01 Berlin-Chemie Ag CANCER POLYTHERAPY INCLUDING AN FLT3 INHIBITOR
TW202440093A (zh) * 2023-03-06 2024-10-16 香港商英矽智能科技知識產權有限公司 Cdk8/19雙重抑制劑及其使用方法
CN120004808B (zh) * 2023-11-15 2025-11-25 宜昌人福药业有限责任公司 一种2-溴-5,6-二氯-1h-苯并咪唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1122988A (en) * 1964-10-22 1968-08-07 Fisons Pest Control Ltd Benzimidazole derivatives
FR1469504A (fr) * 1964-10-22 1967-02-17 Fisons Pest Control Ltd Composés insecticides
DE3227893A1 (de) * 1982-07-26 1984-01-26 Macherey-Nagel & Co Chemikalienhandel, 5160 Düren Verwendung von benzimidazolderivaten zum nachweis von blut und anderen peroxidatisch wirksamen substanzen in koerperfluessigkeiten und ausscheidungsprodukten, insbesondere als diagnostikum in form eines testpapiers
GB9600142D0 (en) 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
JP2001518470A (ja) * 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
TR200101498T2 (tr) * 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
WO2006134318A1 (en) 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
US8975247B2 (en) * 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP2015532650A (ja) 2012-09-05 2015-11-12 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 非生物的植物ストレスに対する活性物質としての置換された2−アミドベンズイミダゾール類、2−アミドベンゾオキサゾール類および2−アミドベンゾチアゾール類またはそれらの塩の使用
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors

Also Published As

Publication number Publication date
MX369589B (es) 2019-11-13
US10174013B2 (en) 2019-01-08
PL2935244T3 (pl) 2019-02-28
IL239193A0 (en) 2015-07-30
KR20150095908A (ko) 2015-08-21
HRP20181429T1 (hr) 2018-11-30
US20150336967A1 (en) 2015-11-26
WO2014096388A2 (en) 2014-06-26
US9388192B2 (en) 2016-07-12
RS57658B1 (sr) 2018-11-30
HRP20181429T8 (hr) 2018-12-28
CA2896156A1 (en) 2014-06-26
US20170152249A1 (en) 2017-06-01
DK2935244T3 (en) 2018-09-10
BR112015014701B1 (pt) 2022-11-01
SI2935244T1 (sl) 2019-01-31
MX2015007057A (es) 2016-01-20
JP2016503779A (ja) 2016-02-08
CN104936951A (zh) 2015-09-23
CN104936951B (zh) 2018-02-06
HUE039376T2 (hu) 2018-12-28
AU2013366513B2 (en) 2016-09-01
EP2935244B1 (en) 2018-06-27
WO2014096388A3 (en) 2014-08-21
KR101779272B1 (ko) 2017-09-18
BR112015014701A2 (pt) 2017-07-11
CA2896156C (en) 2018-05-22
LT2935244T (lt) 2018-10-25
EP2935244A2 (en) 2015-10-28
JP6169185B2 (ja) 2017-07-26
BR112015014701B8 (pt) 2022-12-13
AU2013366513A1 (en) 2015-06-11
CY1120692T1 (el) 2019-12-11
GB201223265D0 (en) 2013-02-06
ES2688395T3 (es) 2018-11-02
PT2935244T (pt) 2018-10-22

Similar Documents

Publication Publication Date Title
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
IL261282A (en) Furinone compounds as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
SI2917217T1 (sl) Substituirani triciklični benzimidazoli kot inhibitorji kinaz
ZA201406078B (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
LT3181567T (lt) Pirazolpirimidino junginiai kaip kinazės slopikliai
SMT201700052T1 (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
ZA201301951B (en) Benzimidazole derivatives as p13 kinase inhibitors
AP2013007252A0 (en) Heterocyclic compounds as kinase inhibitors
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201502838B (en) Quinazolinone derivatives as parp inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
LT2912041T (lt) Tetrahidropiroltiazino dariniai kaip bace slopikliai
EP2838531A4 (en) INDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
EP2895166A4 (en) AMINOISOQUINOLINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
IL235935A0 (en) Transmutable kinase inhibitor picolinamides